Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–10 of 10 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seasonal Allergic Conjunctivitis Clear all
Completed Phase 3 Interventional Results available

Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis

NCT05591755
View directory record Official record
Conditions
Seasonal Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/ Ketotifen Fumarate 0.035% Ophthalmic Solution, Ketotifen fumarate ophthalmic solution 0.035%, Brimonidine tartrate ophthalmic solution 0.025%, Experimental: Vehicle ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Louisville, Kentucky • Andover, Massachusetts • Goodlettsville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Nov 13, 2026, 2:34 PM EST
Completed Phase 2 Interventional Results available

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

NCT03682965
View directory record Official record
Conditions
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
Interventions
Intra-lymphatic allergenic extract, Intra-lymphatic placebo
Biological
Lead sponsor
Christopher Thompson, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Austin, Texas • Grapevine, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Nov 13, 2026, 2:34 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

NCT01174823
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
bepotastine besilate ophthalmic solution, placebo comparator ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
12 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Nov 13, 2026, 2:34 PM EST
Completed Phase 3 Interventional

Evaluation of Efficacy of Ophthalmic Solution in Seasonal Allergic Conjunctivitis

NCT00364091
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
R89674 0.025% ophthalmic solution
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
6
States / cities
Louisville, Kentucky • North Andover, Massachusetts • Creve Coeur, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Nov 13, 2026, 2:34 PM EST
Completed No phase listed Observational

Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)

NCT00985296
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Nov 13, 2026, 2:34 PM EST
Recruiting Phase 2 Interventional

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

NCT07220408
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
TL-925, Placebo
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Smyrna, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Nov 13, 2026, 2:34 PM EST
Completed No phase listed Observational

A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube

NCT00985075
View directory record Official record
Conditions
Allergic Rhinoconjunctivitis
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Nov 13, 2026, 2:34 PM EST
Completed Phase 1Phase 2 Interventional Results available

A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis

NCT03660878
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Nov 13, 2026, 2:34 PM EST
Completed Phase 2 Interventional

Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR

NCT00574379
View directory record Official record
Conditions
Seasonal Allergic Rhinitis, Hay Fever, Allergic Conjunctivitis, Hypersensitivity
Interventions
Bilastine, Placebo
Drug
Lead sponsor
Faes Farma, S.A.
Industry
Eligibility
12 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Oklahoma City, Oklahoma • Austin, Texas • Kerrville, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 13, 2026, 2:34 PM EST
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

NCT04709575
View directory record Official record
Conditions
Allergic Rhinitis, Conjunctivitis
Interventions
REGN5713, REGN5714, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
14
States / cities
Bangor, Maine • Baltimore, Maryland • Plymouth, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Nov 13, 2026, 2:34 PM EST